1
|
Antidiabetic Effects of Bisamide Derivative of Dicarboxylic Acid in Metabolic Disorders. Int J Mol Sci 2020; 21:ijms21030991. [PMID: 32028560 PMCID: PMC7037053 DOI: 10.3390/ijms21030991] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Revised: 01/31/2020] [Accepted: 01/31/2020] [Indexed: 01/02/2023] Open
Abstract
In clinical practice, the metabolic syndrome can lead to multiple complications, including diabetes. It remains unclear which component of the metabolic syndrome (obesity, inflammation, hyperglycemia, or insulin resistance) has the strongest inhibitory effect on stem cells involved in beta cell regeneration. This makes it challenging to develop effective treatment options for complications such as diabetes. In our study, experiments were performed on male C57BL/6 mice where metabolic disorders have been introduced experimentally by a combination of streptozotocin-treatment and a high-fat diet. We evaluated the biological effects of Bisamide Derivative of Dicarboxylic Acid (BDDA) and its impact on pancreatic stem cells in vivo. To assess the impact of BDDA, we applied a combination of histological and biochemical methods along with a cytometric analysis of stem cell and progenitor cell markers. We show that in mice with metabolic disorders, BDDA has a positive effect on lipid and glucose metabolism. The pancreatic restoration was associated with a decrease of the inhibitory effects of inflammation and obesity factors on pancreatic stem cells. Our data shows that BDDA increases the number of pancreatic stem cells. Thus, BDDA could be used as a new compound for treating complication of the metabolic syndrome such as diabetes.
Collapse
|
2
|
Solis MA, Moreno Velásquez I, Correa R, Huang LLH. Stem cells as a potential therapy for diabetes mellitus: a call-to-action in Latin America. Diabetol Metab Syndr 2019; 11:20. [PMID: 30820250 PMCID: PMC6380040 DOI: 10.1186/s13098-019-0415-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2018] [Accepted: 02/13/2019] [Indexed: 02/06/2023] Open
Abstract
Latin America is a fast-growing region that currently faces unique challenges in the treatment of all forms of diabetes mellitus. The burden of this disease will be even greater in the coming years due, in part, to the large proportion of young adults living in urban areas and engaging in unhealthy lifestyles. Unfortunately, the national health systems in Latin-American countries are unprepared and urgently need to reorganize their health care services to achieve diabetic therapeutic goals. Stem cell research is attracting increasing attention as a promising and fast-growing field in Latin America. As future healthcare systems will include the development of regenerative medicine through stem cell research, Latin America is urged to issue a call-to-action on stem cell research. Increased efforts are required in studies focused on stem cells for the treatment of diabetes. In this review, we aim to inform physicians, researchers, patients and funding sources about the advances in stem cell research for possible future applications in diabetes mellitus. Emerging studies are demonstrating the potential of stem cells for β cell differentiation and pancreatic regeneration. The major economic burden implicated in patients with diabetes complications suggests that stem cell research may relieve diabetic complications. Closer attention should be paid to stem cell research in the future as an alternative treatment for diabetes mellitus.
Collapse
Affiliation(s)
| | | | - Ricardo Correa
- Department of Medicine, Warren Alpert School of Medicine, Brown University, Rhode Island, USA
- Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ USA
| | - Lynn L. H. Huang
- Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
- Research Center of Excellence in Regenerative Medicine, National Cheng Kung University, Tainan, Taiwan
| |
Collapse
|
3
|
Role of β Cell Precursors in the Regeneration of Insulin-Producing Pancreatic β Cells under the Influence of Glucagon-Like Peptide 1. Bull Exp Biol Med 2018; 165:644-648. [PMID: 30225696 DOI: 10.1007/s10517-018-4232-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Indexed: 10/28/2022]
Abstract
The effects of the pegylated form of glucagon-like peptide 1 (pegGLP-1) on oligopotent β cell precursors (CD45-TER119-CD133+CD49flow) in the pancreas were studied in C57Bl/6 mice. Under conditions of streptozotocin-induced type 1 diabetes mellitus, intraperitoneal injection of pegGLP1 increased the content of β cell precursors and dithizone-stained cells in the pancreas. β Cell precursors of mice with diabetes demonstrated high self-maintenance potential. In contrast to pegGLP-1, native GLP-1 did not affect β cell precursors in diabetic animals. Treatment of a culture of β cell precursors from mice with diabetes induced the yield of dithizone-stained mononuclears. In conditioned mediums of dithizone-positive cells obtained as a result of differentiation of β cell precursors from mice with diabetes, insulin was detected after administration of pegGLP-1 (10-7 M) and glucose (3 mmol/liter); the level of insulin increased with increasing glucose concentration (to 20 mmol/liter). The in vitro effect of pegGLP-1 did not differ from the effect of GLP-1 (10-7 M).
Collapse
|
4
|
Skurikhin EG, Pakhomova AV, Pershina OV, Krupin VA, Ermakova NN, Pan ES, Kudryashova AI, Ermolaeva LA, Khmelevskaya ES, Goldberg VE, Zhdanov VV, Dygai AM. Role of Sertoli and Leydig Cells in the Regulation of Spermatogonial Stem Cell and Development of Reproductive Disorders in Male C57Bl/6 Mice with Type 1 Diabetes Mellitus. Bull Exp Biol Med 2017; 164:127-131. [PMID: 29181661 DOI: 10.1007/s10517-017-3940-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Indexed: 02/07/2023]
Abstract
Course administration streptozotocin to male C57Bl/6 mice induces a complex of symptoms typical of type 1 diabetes mellitus: hyperglycemia and insulin deficiency, focal inflammatory infiltration of the pancreas, destructive changes in the Langerhans islets, damage to the insular apparatus (reduced number of PDX1+ cells and insulin expression by the secreting cells). Male reproductive disorder are serious complications of type 1 diabetes mellitus. In "diabetic" mice, interstitial edema with inflammatory infiltration and microvascular disorders in the testicular tissue are observed, the number of endothelial precursors (CD45-/CD31+) and the total number and percentage of motile spermatozoa decreased, immature spermatogenic epithelium cells are desquamated of into the lumen of the tubules. Disturbances in the proliferation and differentiation of various spermatogonial stem cell populations (c-kit-/CD90+, c-kit+/CD90+, and CD51-/CD24+/CD52+) in diabetes can be explained by the inhibitory influence of inflammatory factors on testosterone-producing Leydig cells.
Collapse
MESH Headings
- Animals
- Antigens, CD/genetics
- Antigens, CD/metabolism
- Cell Count
- Cell Differentiation/drug effects
- Cell Movement
- Cell Proliferation/drug effects
- Diabetes Mellitus, Experimental/chemically induced
- Diabetes Mellitus, Experimental/genetics
- Diabetes Mellitus, Experimental/metabolism
- Diabetes Mellitus, Experimental/pathology
- Diabetes Mellitus, Type 1/genetics
- Diabetes Mellitus, Type 1/metabolism
- Diabetes Mellitus, Type 1/pathology
- Endothelial Progenitor Cells/drug effects
- Endothelial Progenitor Cells/metabolism
- Endothelial Progenitor Cells/pathology
- Erectile Dysfunction/chemically induced
- Erectile Dysfunction/genetics
- Erectile Dysfunction/metabolism
- Erectile Dysfunction/pathology
- Gene Expression
- Homeodomain Proteins/genetics
- Homeodomain Proteins/metabolism
- Insulin/genetics
- Insulin/metabolism
- Islets of Langerhans/drug effects
- Islets of Langerhans/metabolism
- Islets of Langerhans/pathology
- Leydig Cells/drug effects
- Leydig Cells/metabolism
- Leydig Cells/pathology
- Male
- Mice
- Mice, Inbred C57BL
- Oligospermia/chemically induced
- Oligospermia/genetics
- Oligospermia/metabolism
- Oligospermia/pathology
- Sertoli Cells/drug effects
- Sertoli Cells/metabolism
- Sertoli Cells/pathology
- Spermatogenesis/drug effects
- Spermatogenesis/genetics
- Spermatogonia/drug effects
- Spermatogonia/metabolism
- Spermatogonia/pathology
- Spermatozoa/drug effects
- Spermatozoa/metabolism
- Spermatozoa/pathology
- Streptozocin/toxicity
- Trans-Activators/genetics
- Trans-Activators/metabolism
Collapse
Affiliation(s)
- E G Skurikhin
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - A V Pakhomova
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia.
| | - O V Pershina
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - V A Krupin
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - N N Ermakova
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - E S Pan
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - A I Kudryashova
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - L A Ermolaeva
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - E S Khmelevskaya
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - V E Goldberg
- Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, Russia
| | - V V Zhdanov
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - A M Dygai
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| |
Collapse
|
5
|
Skurikhin EG, Stronin OV, Epanchintsev AA, Pershina OV, Ermakova NN, Krupin VA, Pakhomova AV, Vaizova OE, Dygai AM. Effects of Pegylated Glucagon-Like Peptide-1 Analogue in C57Bl/6 Mice under Optimal Conditions and During Streptozotocin-Induced Diabetes. Bull Exp Biol Med 2017; 163:635-638. [PMID: 28948559 DOI: 10.1007/s10517-017-3867-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Indexed: 01/18/2023]
Abstract
Biological activity of a new pegylated form of an of glucagon-like peptide-1 (GLP-1) analogue pegGLP-1 was studied in C57Bl/6 mice under normal conditions and during modeling of streptozotocin-induced type I diabetes mellitus. pegGLP-1 differs from GLP-1 (7-37) by polyethylene glycol residue covalently bound to His7, Lys26, and Lys34 of the GLP-1 molecule. It was shown that single intragastrical administration of pegGLP-1 induced an increase in GLP-1 level in blood serum of healthy mice. The maximum level of this parameter was observed in 4-8 h. pegGLP-1 elimination half-time was 8.5 h and mean retention time was 15 h. Administration of pegGLP-1 to animals with modeled type I diabetes mellitus was followed by an increase in the levels of GLP-1 and insulin in blood serum, produced a hypoglycemic effect, and improved the parameters of glucose-tolerance test. Biological activity of pegGLP-1 was higher than activity of GLP-1.
Collapse
Affiliation(s)
- E G Skurikhin
- Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences, Tomsk, Russia.
| | - O V Stronin
- Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences, Tomsk, Russia
| | - A A Epanchintsev
- Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences, Tomsk, Russia
| | - O V Pershina
- Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences, Tomsk, Russia
| | - N N Ermakova
- Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences, Tomsk, Russia
| | - V A Krupin
- Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences, Tomsk, Russia
| | - A V Pakhomova
- Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences, Tomsk, Russia
| | - O E Vaizova
- Department of Pharmacology, Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia
| | - A M Dygai
- Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences, Tomsk, Russia
| |
Collapse
|
6
|
Skurikhin EG, Pakhomova AV, Ermakova NN, Pershina OV, Krupin VA, Pan ES, Kudryashova AI, Ermolaeva LA, Dygai AM. Role of Tissue-Specific Stem and Progenitor Cells in the Regeneration of the Pancreas and Testicular Tissue in Diabetic Disorders. Bull Exp Biol Med 2016; 162:146-152. [PMID: 27878497 DOI: 10.1007/s10517-016-3564-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2016] [Indexed: 11/26/2022]
Abstract
Using the model of hypogonadism in C57Bl/6 male mice, we showed that injection of streptozotocin to newborn animals and high-fat diet induced serum IFN-γ and IL-17 elevation, glucose metabolism disturbances, insulin resistance, destructive changes of the Langerhans islets (deficit of PDX1+β cells), while the number of oligopotent β cell precursors (CD45-TER119-CD133+CD49flow) increased. Diabetes played the role of an inducer of testicular tissue inflammation (pan-hemopoietic cell infiltration, increase of IL-2, IL-17, and IL-23 content) and reproductive system disturbances in mice (decrease in free testosterone concentration, suppression of spermatogenesis, and infertility). The development of hypogonadism was paralleled by an increase in the count of spermatogonial stem cells (CD117+CD29+CD90+), multipotent mesenchymal stromal cells (CD45-CD31-CD90+CD106+), hemangiogenesis precursors (CD45-CD117+Flk1+), and epithelial cells (CD45-CD31-CD49f+CD326+).
Collapse
Affiliation(s)
- E G Skurikhin
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - A V Pakhomova
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia.
| | - N N Ermakova
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - O V Pershina
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - V A Krupin
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - E S Pan
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - A I Kudryashova
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - L A Ermolaeva
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| | - A M Dygai
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
| |
Collapse
|
7
|
Dygai AM, Skurikhin EG, Pershina OV, Ermakova NN, Krupin VA, Ermolaeva LA, Stakheeva MN, Choinzonov EL, Goldberg VE, Reikhart DV, Ellinidi VN, Kravtsov VY. Role of Hematopoietic Stem Cells in Inflammation of the Pancreas during Diabetes Mellitus. Bull Exp Biol Med 2016; 160:474-9. [PMID: 26906195 DOI: 10.1007/s10517-016-3200-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Indexed: 02/04/2023]
Abstract
The model of streptozotocin-induced diabetes mellitus in C57Bl/6 mice was employed to study the role of precursors of insulin-producing β-cells, hematopoietic stem cells, and progenitor hematopoietic cells in inflammation. In addition to provoking hyperglycemia, streptozotocin elevated serum levels of IL-1β and hyaluronic acid, induced edema in the pancreatic insular tissue and its infiltration by inflammatory cells (neutrophils, lymphocytes, and macrophages) and fibroblasts. Inflammation in pancreatic islets was accompanied by necrotic processes and decreasing counts of multipotent progenitor β-cells (CD45(-), TER119(-), c-kit-1(-), and Flk-1(-)), oligopotent progenitor β-cells (CD45(-), TER119(-), CD133(+), and CD49f(low)), and insulinproducing β-cells (Pdx1(+)). Pancreatic infl ammation was preceded by elevation of the number of short-term hematopoietic stem cells (Lin-Sca-1(+)c-kit(+)CD34(+)) relative to long-term cells (Lin(-)Sca-1(+)c-kit(+)CD34(-)) in the bone marrow as well as recruitment of hematopoietic stem and progenitor cells into circulation. Transplantation of bone marrow hematopoietic stem and progenitor cells from diabetic C57Bl/6 donor mice to recipient CBA mice with 5-fluorouracilinduced leukopenia accelerated regeneration of granulocytopoiesis in recipient mice.
Collapse
Affiliation(s)
- A M Dygai
- E. D. Goldberg Research Institute of Pharmacology and Regene rative Medicine, Tomsk, Russia
| | - E G Skurikhin
- E. D. Goldberg Research Institute of Pharmacology and Regene rative Medicine, Tomsk, Russia.
| | - O V Pershina
- E. D. Goldberg Research Institute of Pharmacology and Regene rative Medicine, Tomsk, Russia
| | - N N Ermakova
- E. D. Goldberg Research Institute of Pharmacology and Regene rative Medicine, Tomsk, Russia
| | - V A Krupin
- E. D. Goldberg Research Institute of Pharmacology and Regene rative Medicine, Tomsk, Russia
| | - L A Ermolaeva
- E. D. Goldberg Research Institute of Pharmacology and Regene rative Medicine, Tomsk, Russia
| | | | | | - V E Goldberg
- Tomsk Research Institute of Oncology, Tomsk, Russia
| | - D V Reikhart
- E. D. Goldberg Research Institute of Pharmacology and Regene rative Medicine, Tomsk, Russia
| | - V N Ellinidi
- A. M. Nikiforov All-Russian Center of Emergency and Radiation Medicine, the Ministry of Emergency Situations, St. Petersburg, Russia
| | - V Yu Kravtsov
- A. M. Nikiforov All-Russian Center of Emergency and Radiation Medicine, the Ministry of Emergency Situations, St. Petersburg, Russia
| |
Collapse
|